Novo Nordisk is making progress toward stabilizing Wegovy supply

Danish pharmaceutical company Novo Nordisk is hard at work with stabilizing the supply of its obesity drug Wegovy, which has been in high demand in the US since its June launch.

Photo: Novo Nordisk / PR

Novo Nordisk is currently making progress in securing its supply of the obesity drug Wegovy, the company reports on its website.

This means that doses of 0.25 mg, 0.5 mg and 1 mg are being replenished, while ongoing delays are still expected for doses of 1.7 mg and 2.4 mg for the rest of the year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs